Cidara Therapeutics (CDTX) News Today $19.18 -0.82 (-4.10%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of DirectorsApril 16 at 8:00 AM | globenewswire.comCidara Therapeutics' (CDTX) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $35.00 target price on shares of Cidara Therapeutics in a research note on Thursday.April 12, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Earns Buy Rating from Needham & Company LLCApril 12, 2025 | americanbankingnews.comBrokerages Set Cidara Therapeutics, Inc. (NASDAQ:CDTX) Price Target at $39.14April 10, 2025 | americanbankingnews.com24,938 Shares in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Bought by ADAR1 Capital Management LLCADAR1 Capital Management LLC bought a new position in Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 24,938 shares of the biotechnology coApril 9, 2025 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of "Buy" from AnalystsCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) has earned an average recommendation of "Buy" from the eight research firms that are covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy raApril 8, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Raised to Sell at StockNews.comStockNews.com upgraded Cidara Therapeutics to a "sell" rating in a report on Friday.April 6, 2025 | marketbeat.comShort Interest in Cidara Therapeutics, Inc. (NASDAQ:CDTX) Expands By 21.9%Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 15th, there was short interest totalling 289,900 shares, an increase of 21.9% from the February 28th total of 237,800 shares. Based on an average daily trading volume, of 122,300 shares, the days-to-cover ratio is currently 2.4 days. Approximately 4.2% of the company's stock are sold short.April 4, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Shares Pass Above 50 Day Moving Average - Time to Sell?Cidara Therapeutics (NASDAQ:CDTX) Stock Price Crosses Above Fifty Day Moving Average - Here's What HappenedApril 3, 2025 | marketbeat.comCidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)April 1, 2025 | globenewswire.comCidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | globenewswire.comElicio Therapeutics appoints Preetam Shah as chief strategy, financial officerMarch 24, 2025 | markets.businessinsider.comCidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and ResponseMarch 19, 2025 | globenewswire.comCidara Therapeutics to present on CD388 at ICAR 2025March 19, 2025 | markets.businessinsider.comCidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025March 18, 2025 | markets.businessinsider.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Large Growth in Short InterestCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the recipient of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 237,800 shares, an increase of 30.7% from the February 13th total of 182,000 shares. Based on an average trading volume of 100,100 shares, the days-to-cover ratio is presently 2.4 days. Currently, 3.5% of the company's shares are sold short.March 18, 2025 | marketbeat.comCidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025March 18, 2025 | globenewswire.comCidara Therapeutics: CD388 preclinical data published in Nature MicrobiologyMarch 17, 2025 | markets.businessinsider.comCidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature MicrobiologyMarch 17, 2025 | globenewswire.comShane Ward Sells 1,664 Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX) StockCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) COO Shane Ward sold 1,664 shares of the company's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $21.96, for a total transaction of $36,541.44. Following the sale, the chief operating officer now directly owns 14,674 shares of the company's stock, valued at $322,241.04. This represents a 10.18 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.March 14, 2025 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Insider Leslie Tari Sells 1,773 SharesCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) insider Leslie Tari sold 1,773 shares of the firm's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $21.96, for a total transaction of $38,935.08. Following the completion of the transaction, the insider now directly owns 16,215 shares in the company, valued at $356,081.40. This represents a 9.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.March 14, 2025 | marketbeat.comInsider Selling: Cidara Therapeutics, Inc. (NASDAQ:CDTX) COO Sells 1,664 Shares of StockMarch 14, 2025 | insidertrades.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Recommendation of "Buy" from AnalystsShares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) have received an average rating of "Buy" from the eight ratings firms that are covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the companMarch 13, 2025 | marketbeat.comCitizens Capital Markets Initiates Coverage of Cidara Therapeutics (CDTX) with Market Outperform RecommendationMarch 13, 2025 | msn.comCidara Therapeutics initiated with an Outperform at Citizens JMPMarch 12, 2025 | markets.businessinsider.comAnalysts Issue Forecasts for CDTX FY2029 EarningsCidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) - HC Wainwright issued their FY2029 earnings estimates for shares of Cidara Therapeutics in a research report issued to clients and investors on Monday, March 10th. HC Wainwright analyst E. Arce forecasts that the biotechnology company will poMarch 12, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Now Covered by Analysts at Citizens JmpCitizens Jmp initiated coverage on Cidara Therapeutics in a report on Wednesday. They issued an "outperform" rating and a $46.00 price target on the stock.March 12, 2025 | marketbeat.comHC Wainwright Has Pessimistic Outlook of CDTX Q1 EarningsCidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) - Analysts at HC Wainwright cut their Q1 2025 EPS estimates for Cidara Therapeutics in a research report issued on Monday, March 10th. HC Wainwright analyst E. Arce now anticipates that the biotechnology company will post earnings of ($5.45) pMarch 12, 2025 | marketbeat.comCidara Therapeutics price target raised to $35 from $24 at H.C. WainwrightMarch 10, 2025 | markets.businessinsider.comCidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $35.00HC Wainwright increased their target price on Cidara Therapeutics from $24.00 to $35.00 and gave the company a "buy" rating in a research note on Monday.March 10, 2025 | marketbeat.comRBC Capital Sticks to Their Buy Rating for Cidara Therapeutics (CDTX)March 7, 2025 | markets.businessinsider.comCidara Therapeutics (NASDAQ:CDTX) Releases Earnings Results, Misses Estimates By $0.10 EPSCidara Therapeutics (NASDAQ:CDTX - Get Free Report) posted its earnings results on Thursday. The biotechnology company reported ($5.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.28) by ($0.10). Cidara Therapeutics had a negative net margin of 289.05% and a negative return on equity of 69.64%.March 7, 2025 | marketbeat.comCidara Therapeutics, Inc.: Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 7, 2025 | finanznachrichten.deCidara Therapeutics reports Q4 EPS ($5.37) vs. (71c) last yearMarch 7, 2025 | markets.businessinsider.comCidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 6, 2025 | globenewswire.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Large Increase in Short InterestCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the recipient of a large increase in short interest in February. As of February 15th, there was short interest totalling 182,000 shares, an increase of 31.5% from the January 31st total of 138,400 shares. Based on an average trading volume of 102,800 shares, the days-to-cover ratio is currently 1.8 days. Approximately 2.6% of the company's stock are short sold.March 5, 2025 | marketbeat.comSix new option listings and one option delisting on February 26thFebruary 26, 2025 | markets.businessinsider.comCidara Therapeutics, Inc.: Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial OfficerFebruary 20, 2025 | finanznachrichten.deCidara Therapeutics appoints Karbe as CFOFebruary 19, 2025 | markets.businessinsider.comCidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial OfficerFebruary 18, 2025 | globenewswire.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Short Interest UpdateCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the recipient of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 138,400 shares, a growth of 27.6% from the January 15th total of 108,500 shares. Currently, 3.0% of the company's stock are sold short. Based on an average trading volume of 90,800 shares, the short-interest ratio is currently 1.5 days.February 18, 2025 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Rating of "Buy" from AnalystsShares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) have earned an average recommendation of "Buy" from the six research firms that are covering the company, MarketBeat reports. Four investment analysts have rated the stock with a buy rating and two have given a strong buy rating toFebruary 16, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Stock Price Crosses Above 50-Day Moving Average - Here's What HappenedCidara Therapeutics (NASDAQ:CDTX) Stock Crosses Above 50-Day Moving Average - Time to Sell?February 14, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Upgraded at Cantor FitzgeraldCantor Fitzgerald raised Cidara Therapeutics to a "strong-buy" rating in a research report on Wednesday.February 6, 2025 | marketbeat.comCidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech ConferenceJanuary 30, 2025 | globenewswire.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Significant Increase in Short InterestCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totalling 77,100 shares, an increase of 113.6% from the December 31st total of 36,100 shares. Based on an average daily volume of 65,900 shares, the days-to-cover ratio is presently 1.2 days. Currently, 1.7% of the shares of the stock are sold short.January 29, 2025 | marketbeat.comCidara Therapeutics assumed with an Overweight at Cantor FitzgeraldJanuary 28, 2025 | markets.businessinsider.comCantor Fitzgerald raises Cidara stock to OverweightJanuary 27, 2025 | msn.comCantor Fitzgerald Reiterates "Overweight" Rating for Cidara Therapeutics (NASDAQ:CDTX)Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Cidara Therapeutics in a report on Monday.January 27, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Share Price Crosses Above 50 Day Moving Average - Should You Sell?Cidara Therapeutics (NASDAQ:CDTX) Stock Passes Above Fifty Day Moving Average - Here's What HappenedJanuary 22, 2025 | marketbeat.com Remove Ads Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address CDTX Media Mentions By Week CDTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CDTX News Sentiment▼0.590.79▲Average Medical News Sentiment CDTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CDTX Articles This Week▼72▲CDTX Articles Average Week Remove Ads Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Arcus Biosciences News Today Chimerix News Today Avid Bioservices News Today Spyre Therapeutics News Today Intellia Therapeutics News Today Zymeworks News Today Vir Biotechnology News Today Nurix Therapeutics News Today Anavex Life Sciences News Today Oculis News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CDTX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryThe crypto summit Wall Street wants to stop Learn how to structure your portfolio like the top hedge funds...Crypto 101 Media | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CDTX Stock Free CDTX Stock Alerts